Western Europe is a regional setting in the medical literature on hepatitis C virus infection, chronic kidney disease, hemodialysis, and transplantation. Its importance lies less in a single location-specific event than in the way it illustrates the transition from widespread transfusion- and healthcare-associated transmission toward lower, though persistent, risks managed through screening and strict infection-control practice.

Epidemiological Setting

Western Europe has reported hepatitis C virus prevalence ranging from 0.4% to 3% of the population. Although this range is lower than the rates described for Eastern Europe and the Middle East, it still represents a substantial burden because many chronically infected people remain unaware of their infection. Historically, infection was acquired largely through parenteral exposure, including blood-product transfusion, intravenous drug use, and unsafe injection procedures.

The safety of blood supplies changed the regional risk profile. In the 1980s, the risk of post-transfusion hepatitis C was about 0.5% per blood unit; with increasingly sensitive donor screening, it fell in the United States to approximately 0.0001%, or one infection per million blood units, with similarly major improvements reported in other Western countries. As transfusion became safer, attention shifted toward intravenous or nasal drug use, mother-to-child transmission, unsafe medical or surgical procedures, and healthcare-associated transmission in settings such as hemodialysis.

Hemodialysis and Healthcare Transmission

Hemodialysis patients were recognized as a high-risk group when serological tests for hepatitis C became available in the 1990s. Early prevalence was high in Western countries, partly because dialysis patients frequently required transfusions. Yet several observations pointed to continuing nosocomial transmission within dialysis units: prevalence correlated with time on dialysis independently of transfusion burden, was higher in hemodialysis than in peritoneal dialysis or home hemodialysis, and remained substantial among some patients who had never received a transfusion.

Western European units responded differently. Spain, where prevalence initially exceeded 30%, adopted isolation of hepatitis C-positive patients by ward or monitor while reinforcing hygienic precautions. Most units in Belgium instead emphasized strengthened hygiene without routine isolation. The argument against isolation included the long interval between infection and seroconversion, the lower infectivity of hepatitis C virus compared with hepatitis B virus, the logistical difficulty of separating patients with different infection statuses, and the possibility of exposure to multiple viral genotypes. Supporters argued that isolation could be justified in units with high recent seroconversion rates.

The subsequent decline in hepatitis C incidence and prevalence in many countries coincided with these interventions, but before-and-after studies could not establish that isolation itself caused the improvement. Molecular studies later confirmed that nosocomial transmission did occur: sequencing identified clusters of closely related viral isolates among patients treated in the same units. A review of 20 such studies found that failures in infection-control procedures were the probable cause of new cases, while the internal fluid pathway of the dialysis machine was considered a possible route in only one study. In 18 of the 20 studies, some or all newly infected patients had not shared a dialysis machine with the presumed source patient, indicating that the machine circuit played, at most, a small role.

On that evidence, the KDIGO workgroup did not recommend dedicated dialysis machines for hepatitis C-infected patients and did not recommend isolation as a substitute for strict infection-control procedures. Prospective observational studies, including the Dialysis Outcomes and Practice Patterns Study and an Italian study, found no independent protective effect of isolation after adjustment for confounding factors such as the prevalence of infection within the unit. The central preventive measure remained disciplined hygiene: handwashing before and after patient or equipment contact, gloves at the dialysis station, disposal of single-use items, disinfection or patient dedication of nondisposable equipment, cleaning of contaminated surfaces after each session, appropriate dialyser-reuse procedures where unavoidable, waste management, and regular observational audits.

Changing Regional Risk and Clinical Burden

The epidemiology of hepatitis C in Western European hemodialysis units shifted over time. In the 1990s, infection was often acquired relatively soon after dialysis began; in the new millennium, it was more commonly acquired before dialysis. This change reduced healthcare-associated transmission but also meant that patients could enter dialysis with a longer duration of infection. Because many hepatitis C complications emerge only after decades, longer-standing infection may increase the eventual risk of cirrhosis and hepatocellular carcinoma, making careful liver follow-up important even when dialysis-unit transmission has declined.

Current anti-hepatitis C antibody prevalence is below 10% in most, though not all, countries. Very high rates above 20% can still occur where societal crisis, war, or poor economic conditions weaken chronic hemodialysis programs and staff training. The high viral safety of blood transfusions achieved in Western countries therefore cannot simply be assumed in every setting. Outbreaks or isolated cases of transmission may still occur, and a low average incidence does not eliminate the need for surveillance and procedural discipline.

Hepatitis C also bears on renal disease beyond transmission. Infected patients, including kidney- or liver-transplant recipients, have an increased risk of glomerular lesions leading to chronic kidney disease, and patients with hepatitis C-associated glomerulonephritis are serum HCV RNA positive even when significant liver disease is absent. A case-series analysis found that hepatitis C seropositivity among patients with membranoproliferative glomerulonephritis was about ten times higher than in hepatitis C-negative patients. Other studies associated infection with a higher risk of chronic kidney disease stages 3–5, a shorter time to chronic kidney disease and end-stage renal disease, and an independent relationship between higher baseline viral load and chronic kidney disease. Albuminuria and proteinuria were also more common in several analyses, although not every study found an association with reduced estimated glomerular filtration rate.

Survival, Quality of Life, and Transplantation

Among patients receiving long-term dialysis, hepatitis C infection is associated with poorer survival. A meta-analysis of seven observational studies involving 11,589 dialysis patients estimated an adjusted all-cause mortality relative risk of 1.34 for those with anti-hepatitis C antibodies. Hepatocellular carcinoma and cirrhosis were more frequent causes of death in antibody-positive patients, and the unadjusted liver-related mortality risk was estimated at 5.89. The literature also describes an excess cardiovascular risk and a possible contribution from diminished quality of life, although one meta-analysis found an unadjusted relative risk of 0.95 for cardiovascular mortality, without statistical significance.

Quality-of-life effects are not limited to liver pathology. In a study of 165 regular dialysis patients, 83 of whom were anti-hepatitis C positive, antibody positivity was independently associated with a lower mental component score on the SF-36 questionnaire, while no association was found with the physical component score. Depression, fatigue, cognitive impairment, concern about long-term health, and the burdens of hemodialysis may all contribute. It remains uncertain whether antiviral treatment would reduce mortality through quality-of-life improvement independently of liver histology or virological markers, but patients with advanced liver disease might still gain an important quality-of-life benefit.

The same regional transplant framework emphasizes systematic evaluation before kidney transplantation. Studies report advanced liver injury, including stage 3 or 4 disease and cirrhosis, in 10%–25% of candidates when liver biopsy is performed during assessment. Candidates should be screened for anti-hepatitis C antibody and, where appropriate, active viremia by nucleic acid testing. Liver biopsy remains the reference method for assessing advanced liver disease when active infection is present, and established or decompensated cirrhosis warrants referral for consideration of simultaneous liver–kidney transplantation. Patients on the waiting list require regular monitoring, particularly when waiting times approach five to seven years.

Western European transplantation practice also illustrates the changing value of infected organs. Kidneys from hepatitis C-positive donors remain controversial, but center-based and registry experience indicates that their use in hepatitis C-positive recipients can be safe over the long term, with favorable graft survival, patient survival, and hepatitis C-related liver outcomes. International recommendations therefore limit this strategy to recipients who have positive HCV RNA while waiting and who consent in advance. Matching donor and recipient viral genotypes may reduce the risk of superinfection, although this is difficult under time constraints, and donor HCV RNA information has not always been available. As infection prevalence falls and more patients receive treatment before listing, suitable recipients become fewer, leaving some hepatitis C-positive kidneys unused despite severe organ shortage.

Regional Significance

Western Europe functions as a benchmark for the epidemiological transition in hepatitis C care. Safer blood supplies reduced transfusion transmission; molecular virology made dialysis-unit transmission visible; and infection-control policy shifted from uncertain reliance on isolation toward standardized hygiene. At the same time, lower transmission rates did not erase the consequences of infections acquired decades earlier, which continue to shape liver disease, chronic kidney disease, survival, mental well-being, and transplant eligibility.

The region therefore represents a balance between declining infection risk and persistent clinical consequences. Its experience supports careful distinction between antibody positivity and active viremia, continued monitoring of dialysis and transplant populations, evidence-based infection-control measures rather than unsupported assumptions about dedicated machines or isolation, and a willingness to use otherwise discarded hepatitis C-positive kidneys when recipient selection, informed consent, virological assessment, and organizational coordination make the balance favorable.